Brookline notes that the announcement that Biogen (BIIB) is advancing its first candidate from its C4 Therapeutics (CCCC) collaboration towards the clinic supports the firm’s outlook for collaboration revenue for the latter but importantly, offers potential longer term revenue upside for C4 from royalties from this candidate, BIIB142, and IRAK4 degrader. The firm believes the clinical progress with BIIB142, as well as potential development of the second candidate delivered under the Biogen collaboration, offer the potential for very large markets with unmet need. Brookline has a Buy rating on C4 with a price target of $50.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCCC: